Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509052 · ClinicalTrials.gov registry record · Phase 1
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02509052 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT02509052, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Leflunomide
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02509052
The ClinicalTrials.gov registry entry for NCT02509052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02509052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02509052 about?
NCT02509052 is a clinical study titled "Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase I/II trial studies the side effects and best dose of leflunomide in treating patients with multiple myeloma that has come back (relapsed) or has not responded to previous treatment (refractory). Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cel...
What is the current status of trial NCT02509052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-12-02. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT02509052?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Leflunomide (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02509052?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.